Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Free Cash Flow (2019 - 2025)

Allogene Therapeutics' Free Cash Flow history spans 7 years, with the latest figure at -$29.9 million for Q3 2025.

  • For Q3 2025, Free Cash Flow rose 32.82% year-over-year to -$29.9 million; the TTM value through Sep 2025 reached -$159.0 million, up 27.05%, while the annual FY2024 figure was -$201.0 million, 15.99% up from the prior year.
  • Free Cash Flow for Q3 2025 was -$29.9 million at Allogene Therapeutics, up from -$39.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$29.9 million in Q3 2025 and bottomed at -$70.1 million in Q1 2022.
  • The 5-year median for Free Cash Flow is -$53.9 million (2023), against an average of -$52.3 million.
  • The largest annual shift saw Free Cash Flow tumbled 82.48% in 2021 before it skyrocketed 38.54% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$46.2 million in 2021, then tumbled by 38.15% to -$63.8 million in 2022, then rose by 15.52% to -$53.9 million in 2023, then surged by 31.42% to -$37.0 million in 2024, then rose by 19.01% to -$29.9 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Free Cash Flow are -$29.9 million (Q3 2025), -$39.1 million (Q2 2025), and -$53.0 million (Q1 2025).